<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9111376</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2201</journal-id>
<journal-id journal-id-type="nlm-ta">Curr Opin Neurobiol</journal-id>
<journal-id journal-id-type="iso-abbrev">Curr. Opin. Neurobiol.</journal-id>
<journal-title-group>
<journal-title>Current opinion in neurobiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0959-4388</issn>
<issn pub-type="epub">1873-6882</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26705693</article-id>
<article-id pub-id-type="pmc">4738077</article-id>
<article-id pub-id-type="doi">10.1016/j.conb.2015.11.003</article-id>
<article-id pub-id-type="manuscript">NIHMS745480</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling Psychiatric Disorders with Patient-derived iPSCs</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wen</surname>
<given-names>Zhexing</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Christian</surname>
<given-names>Kimberly M.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Song</surname>
<given-names>Hongjun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ming</surname>
<given-names>Guo-li</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="corresp" rid="cor1">#</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Institute for Cell Engineering, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA</aff>
<aff id="A2"><label>2</label>Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA</aff>
<aff id="A3"><label>3</label>The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA</aff>
<aff id="A4"><label>4</label>Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA</aff>
<author-notes>
<corresp id="cor1"><label>#</label>Correspondence should be addressed to: Guo-li Ming, M.D. &amp; Ph.D., Institute for Cell Engineering, Johns Hopkins University School of Medicine, 733 N. Broadway, MRB779, Baltimore, MD 21205, USA, Tel: 443-287-7498; Fax: 410-614-9568, <email>gming1@jhmi.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>18</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>17</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2017</year>
</pub-date>
<volume>36</volume>
<fpage>118</fpage>
<lpage>127</lpage>
<!--elocation-id from pubmed: 10.1016/j.conb.2015.11.003-->
<abstract>
<p id="P1">Psychiatric disorders are heterogeneous disorders characterized by complex genetics, variable symptomatology, and anatomically distributed pathology, all of which present challenges for effective treatment. Current treatments are often blunt tools used to ameliorate the most severe symptoms, often at the risk of disrupting functional neural systems, thus there is a pressing need to develop rational therapeutics. Induced pluripotent stem cells (iPSCs) reprogrammed from patient somatic cells offers an unprecedented opportunity to recapitulate both normal and pathologic human tissue and organ development, and provides new approaches for understanding disease mechanisms and for drug discovery with higher predictability of their effects in humans. Here we review recent progress and challenges in using human iPSCs for modeling neuropsychiatric disorders and developing novel therapeutic strategies.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>